On-Demand: Advancing Care for Patients With Resectable NSCLC

Wednesday, November 20, 2024

Location: Grapevine Ballroom

CE: 1.00 credits/hours

Speaker(s)

Danielle M. Fournier, DNP, APRN, AGPCNP-BC, AOCNP (she/her/hers)

Advanced Practice Registered Nurse
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Sarah Anderson, MSN, APRN, AGNP-C, AOCNP

Advanced Practice Registered Nurse
The University of Texas MD Anderson Cancer Center
Pearland, Texas, United States

Danielle M. Fournier has no relevant financial relationships to disclose.
Sarah Anderson has no relevant financial relationships to disclose.

Recall relevant clinical trials leading to recent FDA approvals of new systemic treatment options for patients with resectable non-small cell lung cancer (NSCLC), and related updates to clinical practice guidelines
Identify recommended biomarker tests needed to plan treatment for patients with resectable NSCLC
Incorporate evidence-based best practices for monitoring and managing adverse events associated with neoadjuvant and adjuvant systemic therapy for patients with resectable NSCLC